LONDON: AstraZeneca announced that its drug Truqap (capivasertib) has received approval from the US Food and Drug Administration (FDA) for the treatment of a specific type of advanced breast cancer. Truqap is a first-in-class medicine that targets the PI3K/AKT pathway, which is involved in cancer growth and resistance to therapy. Truqap is approved for use…